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Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. 
Transcriptional inhibitors, however, may offer inroads into targeting these cancers. Through 
chemical genomics screening, we identified that Ewing sarcoma is a disease with preferential 
sensitivity to THZ1, a covalent small molecule CDK7/12/13 inhibitor. The selective CDK12/13 
inhibitor, THZ531, impairs DNA damage repair in an EWS/FLI dependent manner, supporting a 
synthetic lethal relationship between response to THZ1/THZ531 and EWS/FLI expression. The 
combination of these molecules with PARP inhibitors showed striking synergy in cell viability and 
DNA damage assays in vitro and in multiple models of Ewing sarcoma, including a PDX, in vivo 
without hematopoietic toxicity.
IN BRIEF/eTOC
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Iniguez et al. find that inhibition of CDK12 is synthetic lethal with EWS/FLI expression. 
CDK12/13 inhibitors impair DNA damage repair in cells expressing EWS/FLI, and the 
combination of CDK12/13 and PARP inhibitors synergistically reduces tumor growth and extends 
survival in Ewing sarcoma mouse models.
INTRODUCTION
A therapeutic challenge in oncology is the paucity of readily “druggable” genetic events in 
many malignancies, particularly childhood cancers. These tumors are frequently defined by 
sentinel abnormalities involving transcription factors in an otherwise quiet genomic 
landscape. Ewing sarcoma, the second most common cancer involving bone in children, is 
characterized by a chromosomal rearrangement that fuses the strong transactivation domain 
of the RNA binding protein, EWS, with the DNA binding domain of an ETS protein, most 
commonly FLI1. EWS/FLI acts as both a transcriptional activator and a transcriptional 
repressor via distinct chromatin binding mechanisms (Riggi et al., 2014), and numerous 
studies have demonstrated a strict dependency on EWS/FLI in Ewing sarcoma cells, 
supporting the targeting of this fusion protein or its transcriptional output (Hu-Lieskovan et 
al., 2005; Smith et al., 2006). Moreover, three recent massively parallel sequencing efforts 
revealed that Ewing sarcoma tumors possess very low mutation rates, harboring few 
recurrent mutations other than EWS/ETS rearrangements (Brohl et al., 2014; Crompton et 
al., 2014; Tirode et al., 2014).
One approach to treating these tumors is the direct targeting of the aberrant transcription 
factor. With a few notable exceptions, however, this approach poses a significant drug 
discovery challenge. A second approach might target a synthetic lethal dependency imparted 
on the cell by virtue of the cancer-promoting genetic event, such as the use of PARP 
inhibitors in BRCA1- and BRCA2-mutant cancers (Sonnenblick et al., 2015). A third 
approach might target basic transcriptional machinery with transcriptional inhibitors, such as 
the FDA-approved drug actinomycin D, or compounds such as THZ1, a small-molecule 
covalent inhibitor of CDK7/12/13.
Initial studies demonstrated that CDK7/12/13 inhibition with THZ1 may be therapeutically 
beneficial in tumor types that are highly dependent on transcriptional programs for initiating 
a transformed phenotype (Kwiatkowski et al., 2014). These studies provided rationale for an 
inroad into treating cancers defined by aberrant transcription factors. For example, MYCN-
amplified neuroblastoma cells were found to be highly responsive to THZ1 through 
suppression of the MYCN transcriptional program, and T cell acute lymphoblastic leukemia 
cells (T-ALL) were responsive to THZ1 through the repression of RUNX1 (Chipumuro et 
al., 2014; Kwiatkowski et al., 2014). THZ1 decreases the phosphorylation of the C-terminal 
domain (CTD) of RNA Polymerase II (RNA Pol II), thereby preventing transcriptional 
initiation and elongation. Exquisite specificity is obtained through binding of the molecule 
to a cysteine residue adjacent to the ATP binding domain (Kwiatkowski et al., 2014). The 
capacity to perform at scale chemical genomic screening across over one-thousand cancer 
cell lines provided an unprecedented opportunity to discover new connections between 
response to THZ1 and the expression of other so-called “undruggable” targets.
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RESULTS
Ewing sarcoma is highly sensitive to the CDK7/12/13 inhibitor THZ1
THZ1, a covalent and potent inhibitor of CDK7/12/13 kinases involved in transcriptional 
regulation, recently emerged as a targeted strategy to impair aberrant transcription 
(Chipumuro et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 2014). In order to 
identify biomarkers of sensitivity to THZ1, we screened THZ1 against a diverse panel of 
1,081 cancer cell lines (Figure 1A) (Garnett et al., 2012; Kwiatkowski et al., 2014). Within 
the group of cell lines highly sensitive to low concentrations of THZ1 (defined by cell lines 
with viability <50% when treated with 9.76 nM THZ1), Ewing sarcoma cells were 
significantly enriched for response (Fisher’s test, p=9×10−9). In fact, Ewing sarcoma cell 
lines were collectively more sensitive to THZ1 than other cancer types previously reported 
to be highly sensitive to this molecule (Figure 1A). The mean viability for each tumor type 
screened with 9.76 nM THZ1 was as follows: Ewing sarcoma 47%, T-ALL 58%, lung 
cancer 92%, and neuroblastoma 96%. To assay the on-target activity of THZ1, we measured 
the phosphorylation of global pSer2/5/7 RNA Pol II levels at concentrations that inhibit 
Ewing sarcoma cell growth. THZ1 suppressed the phosphorylation of the CTD of RNA Pol 
II in a concentration-dependent manner (Figure 1B). Suppression of EWS/FLI did not affect 
the ability of THZ1 to repress these phosphorylation sites (Figure S1A). Furthermore, THZ1 
induced apoptosis as demonstrated by an increase in the percentage of Annexin V+ cells and 
PARP cleavage (Figure 1C, D) and strongly decreased the colony formation capacity of 
Ewing sarcoma cell lines (Figure 1E).
To establish the activity of THZ1 in vivo, TC32 Ewing sarcoma xenografts were treated with 
either vehicle control or 10 mg/kg of THZ1 delivered intraperitoneally twice per day. 
Treatment was stopped at day 42 and the remaining mice were followed for survival. THZ1 
as a single agent significantly impaired tumor progression and increased overall survival 
(median survival = 28.5 days for vehicle and 44 days for the THZ1 arms) (Figure 1F, G). No 
weight loss-related toxicity was observed (Figure S1B).
A Primary Target of THZ1 Is CDK12 in Ewing Sarcoma
In order to elucidate preferential dependencies of cancer cells on CDK7, CDK12 and 
CDK13, we used genome-scale CRISPR-Cas9 screening across 341 cancer cell lines 
representing diverse cancer cell types (Meyers et al., 2017). We identified that CDK7 
disruption is pan-lethal with the depletion of guides targeting CDK7 similar to the depletion 
seen for known common essential genes in the screen, raising some concerns about the 
therapeutic window of a potent CDK7 inhibitor (Figure S2A). In contrast, CDK12 and 
CDK13 showed differential dependencies across the cell lines included in the screen (Figure 
S2B, C). We found that approximately 10.2% of the cell lines are dependent on CDK12 with 
a dependency score of <−0.5, as compared to CDK7 and CDK13 where 100% and 3.8% of 
lines screened were dependent on the gene respectively. Among the CDK12 dependent cell 
lines was SK-N-MC, the one Ewing sarcoma cell line included in the screen harboring an 
EWS/FLI rearrangement, with three of the 11 neuroblastoma cell lines included in the 
screen scoring between −0.4 and −0.5. The majority of neuroblastoma cell lines, as well as 
SCLC and T-ALL cell lines, were not dependent on CDK12 for survival (Figure S2B). 
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Furthermore, none of the Ewing sarcoma, neuroblastoma, T-ALL or SCLC cell lines 
screened were dependent on CDK13 (Figure S2C). A full list of all of the CERES 
dependency gene scores for CDK7, CDK12, and CDK13 across the 341 cancer cell lines is 
included in Table S1. These data suggest that the preferential sensitivity of Ewing sarcoma 
cells to THZ1 in our chemical genomics screen may be due to CDK12 and not CDK7 or 
CDK13 inhibition. They also suggest that a more selective CDK12/13 inhibitor would be 
preferentially toxic to Ewing sarcoma cells and may reduce potential toxicities associated 
with CDK7 inhibition. In order to develop more selective molecules, Zhang et al. used 
THZ1 as starting material for THZ531, a first-in-class covalent and selective CDK12 and 
CDK13 inhibitor, which targets a cysteine residue adjacent to the ATP binding site of 
CDK12 and CDK13 (Zhang et al., 2016). The authors reported that THZ531 inhibits 
CDK12 and CDK13 with IC50 concentrations of 158 nM and 69 nM, respectively, whereas, 
THZ531 inhibits CDK7 and CDK9 at 8.5 µM and 10.5 µM, respectively (Zhang et al., 
2016). Furthermore, Kinativ profiling demonstrated that CDK12 and CDK13 were the 
primary targets of THZ531, with none of the other 211 kinases profiled demonstrating >55% 
inhibition (Zhang et al., 2016). In order to identify which kinase target of THZ1 is primarily 
responsible for the potent anti-viability effects observed, we treated a panel of Ewing 
sarcoma cell lines with three compounds: THZ1, a pan CDK7/12/13 inhibitor; THZ531, a 
CDK12/13 selective inhibitor; and THZ531R, a non-cysteine reactive analog with reduced 
anti-CDK12/13 activity (Figure 2A). We found that Ewing sarcoma cell lines were nearly as 
sensitive to THZ531 as they were to THZ1, with IC50 concentrations in the low nanomolar 
range with both small molecules in viability assays (Figure 2A and Table S2). The mean 
IC50 for THZ1 across Ewing sarcoma cell lines was 41.03 nM vs. 90.4 nM for THZ531, 
demonstrating that CDK12/13 inhibition recapitulates much of the sensitivity to THZ1, 
although CDK7 inhibition may still contribute to the sensitivity to this molecule. 
Additionally, Ewing sarcoma cell lines were completely insensitive to THZ531R (Figure 
2A). Furthermore, Ewing sarcoma cell lines were 3–10-fold more sensitive to THZ1 and 
THZ531 than non-EWS/FLI expressing osteosarcoma cell lines (Figure 2A and Table S2), 
suggesting that sensitivity to CDK7/12/13 inhibition may be enhanced in EWS/FLI 
rearranged cells. Interestingly, all ten Ewing sarcoma cell lines tested were uniformly 
sensitive to THZ1 and THZ531, indicating that CDK12/13 inhibition may be broadly 
effective as a treatment strategy for Ewing tumors defined by EWS/FLI rearrangements 
(Table S2).
To confirm the selectivity of these compounds in Ewing sarcoma cells, we performed THZ1-
biotin immunoprecipitation of samples treated with THZ1 or THZ531 and probed for Cyclin 
K (binding partner of CDK12/13) or Cyclin H (binding partner of CDK7). We found that 
THZ531 has specificity for Cyclin K-CDK12/13 complexes and not Cyclin H-CDK7 
complexes as THZ1-biotin can pull down Cyclin H-CDK7 complexes in samples pretreated 
with THZ531, but cannot pull down Cyclin K-CDK12/13 complexes as they are occupied by 
THZ531 (Figure 2B, C).
To provide further validation of the target of THZ531 in Ewing sarcoma cells, Cyclin K was 
knocked down in A673 Ewing sarcoma cells (Figure 2D). Suppression of Cyclin K using 
three different hairpins strongly suppressed the viability of these cells (Figure 2D, E). To 
further discriminate which CDK is responsible for the potent growth suppression with 
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THZ531, we knocked down CDK12 and CDK13 using two different hairpins (Figure 2F). 
We found that genetic suppression of CDK12 decreased the viability of Ewing sarcoma cells 
(Figure 2F, G), while in contrast, suppression of CDK13 had a minimal effect (Figure 2F, 
G). Additionally, CRISPR-Cas9 mediated knockout of CDK12 strongly reduced Ewing 
sarcoma cell viability (Figure 2H, I). Collectively, these results demonstrate that CDK12 
inhibition underlies the enhanced sensitivity of Ewing sarcoma cells to THZ1, and as such, 
we focused on the more selective compound, THZ531.
Cyclin K/CDK12 and Cyclin K/CDK13 complexes were recently identified in human cells 
(Blazek et al. 2011). The Cyclin K/CDK12 complex has been shown to regulate the 
phosphorylation of the CTD of RNA Pol II (Blazek et al., 2011). Consistent with the effects 
of THZ1, THZ531 reduced the phosphorylation of the RNA Pol II CTD at Ser2 and Ser5, 
but in contrast, did not strongly reduce the phosphorylation at Ser7 (Figure S2D). 
Additionally, THZ531 increased PARP cleavage and Annexin V+ cell populations and 
decreased anchorage independent growth in soft agar in Ewing sarcoma cells (Figure S2E–
G).
THZ531 Treatment Preferentially Represses the Expression of DNA Repair-related Genes in 
Ewing Sarcoma Cells
We next performed global gene expression profiling to investigate the effects of THZ531 on 
transcriptional programs in Ewing sarcoma. We profiled two highly sensitive EWS/FLI 
rearranged Ewing sarcoma cell lines, A673 and TC32, for which we have deep genomic 
characterization (Crompton et al., 2014). Samples were treated in duplicate with DMSO or 
THZ531 at 100 nM or 500 nM for 6 hr. THZ531 treatment globally downregulated steady-
state mRNA levels in a concentration-dependent manner (Figure 3A). We observed profound 
gene expression suppression at 500 nM in both cell lines with 22% and 27% of genes 
downregulated >2 linear fold in A673 and TC32 cells respectively (4,159 out of 18,712 
genes in A673 cells and 4,207 out of 15,546 genes in TC32 cells) (Figure 3A). More modest 
effects on gene expression were observed at the 100 nM concentration with 10% and 6.7% 
of genes downregulated > 2-fold in A673 and TC32 cells respectively (1,876 out of 18,712 
genes in A673 cells and 1,142 out of 15,546 genes in TC32 cells) (Figure 3A). Remarkably 
few genes were upregulated by THZ531 at either 100 nM or 500 nM, consistent with the 
known role of CDK12/13 in transcriptional initiation and elongation. The numbers of 
differentially expressed genes observed with THZ531 treatment is consistent with the 
differential expression observed with genetic depletion of CDK12 (Liang et al., 2015). Gene 
expression changes between A673 and TC32 cells were strongly correlated at both 100 nM 
(R2=0.67) and 500 nM (R2 = 0.72) of THZ531 (Figure 3B). Venn diagrams demonstrate the 
significant overlap of downregulated and upregulated genes between the two cell lines 
(Figure S3A, B), indicating a common gene expression response to THZ531.
To elucidate candidate mechanisms of action of THZ531 in Ewing sarcoma, genes were 
ranked from most to least sensitive to 100 nM THZ531, and the top 5% of THZ531-sensitive 
genes (944 genes for A673 and 788 genes for TC32) were subjected to gene ontology 
enrichment using David functional annotation software analysis (Figure 3C). As expected, 
gene sets related to regulation of transcription and replication were enriched among 
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THZ531–responsive genes. Additionally, genes involved in DNA damage repair were 
identified as being preferentially downregulated by THZ531. We then performed Gene Set 
Enrichment Analysis (GSEA) for enrichment in the 5,499 gene sets from the MSigDB v5 
collections, c2 (curated pathways and experimental gene sets) and c5 (Gene Ontology), as 
well as published EWS/FLI genes sets (Figure 3D) (Marques Howarth et al., 2014; Tomazou 
et al., 2015). Several DNA damage response (DDR) gene sets fell above the threshold of 
statistical significance and had negative normalized enrichment scores (NES) (Figure 3D), 
indicating that these gene sets were significantly downregulated by THZ531 treatment in 
both A673 and TC32 cells. DNA damage checkpoint and homologous recombination gene 
sets were among the most depleted by THZ531 treatment (Figure 3E). Furthermore, there 
was a noticeable lack of significant downregulation of EWS/FLI gene sets by THZ531 
treatment in both Ewing sarcoma cell lines (Figure 3D). Lists of all DDR and EWS/FLI 
gene sets are included in Tables S3 and S4 and of all genes affected by THZ531 treatment in 
Table S5.
Several key genes regulating DDR were downregulated by THZ531 in A673 and TC32 cells 
(Figure 3F). We performed a leading edge analysis to identify the genes that form the 
consensus among the DNA damage and repair gene signatures. We found that 33 genes 
belong to at least four of the enriched DNA damage and repair MSigDB gene sets, including 
several genes regulating homologous recombination and UV response (Figure S3C). Low-
throughput validation of select genes (BRCA1, RAD51, FANCF, XRCC2) by qPCR 
confirmed that THZ531 strongly suppresses expression of these genes (Figure S3D).
As THZ1 has been reported to preferentially repress the expression of super-enhancer (SE)-
marked genes, we analyzed the effect of THZ531 on SE-marked gene expression 
(Chipumuro et al., 2014; Christensen et al., 2014; Kwiatkowski et al., 2014). Box plots show 
the log-fold change (LFC) in gene expression of all genes, typical enhancer-associated genes 
(TE), SE genes, and EWS/FLI target genes following THZ531 treatment (Figure S3E). In 
this analysis, enhancers were ranked by H3K27Ac ChIP-sequencing signal, and EWS/FLI 
target genes were identified as 1) genes associated with EWS/FLI ChIP-sequencing signal 
and 2) genes with a decrease in transcript expression following EWS/FLI knockdown in 
A673 cells as described in Riggi et al. 2014 (Riggi et al., 2014). Interestingly, we found that 
SE-associated genes and EWS/FLI target genes were not preferentially repressed by 
THZ531 compared to all genes. This data suggests that CDK12 and CDK13 do not 
preferentially regulate SE-marked or EWS/FLI target genes in Ewing sarcoma.
EWS/FLI Expression Imparts Sensitivity to CDK12 Inhibition and to Molecules Inducing 
DNA Damage
In light of the exceptional sensitivity of Ewing sarcoma cells to THZ531, we hypothesized 
that EWS/FLI may render cells more vulnerable to THZ531 and other DNA damage repair 
inhibitors. Indeed, DNA damaging agents are currently used to treat patients with Ewing 
sarcoma, and Ewing sarcoma cell lines have been reported to be highly sensitive to PARP 
inhibitors (Gill et al., 2015). To test this hypothesis, we knocked down EWS/FLI using a 
TRIPZ inducible system. We found that EWS/FLI suppression using two unique hairpins 
rendered TC32 and A673 cells less sensitive to THZ531 (Figure 3G, H). Furthermore, 
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suppression of EWS/FLI can partially rescue the anti-viability effects of CDK12 knockdown 
(Figure 3I). To rule out the possibility that EWS/FLI knockdown renders resistance to 
THZ531 due to induction of cell cycle arrest, we serum starved A673 and TC32 Ewing 
sarcoma cells to induce growth-arrest (Figure S3F, G) and assayed sensitivity of these cells 
to THZ531. Importantly, unlike cells with EWS/FLI suppression, serum starved cells do not 
display differential sensitivity to THZ531 (Figure S3H, I). Thus, the proliferative 
disadvantage of losing EWS/FLI is not responsible for the increased resistance to THZ531 
as inducing growth-arrest with serum starvation does not engender resistance to these 
molecules. These results suggest that the EWS/FLI oncoprotein imparts vulnerability to 
compounds that induce defects in DNA damage repair and suggest that the presence of 
EWS/FLI itself is synthetic lethal with CDK12 inhibition in Ewing sarcoma cells.
We next mined the Genomics of Drug Sensitivity in Cancer (GDSC) database, a screen of 
1,074 cancer cell lines treated with 265 anti-cancer drugs, to identify additional small 
molecules for which EWS/FLI is a biomarker of response (Yang et al., 2013). There was 
significant enrichment for drugs inducing DNA damage among the compounds in which 
EWS/FLI rearrangement was a biomarker of sensitivity (Figure 3J). Among these 
compounds were mitomycin-C, etoposide, SN-38, camptothecin, and gemcitabine, all of 
which are chemotherapeutic agents that induce DNA damage. EWS/FLI was also a 
biomarker of sensitivity to the ATM inhibitor, CP466722, an interesting finding in light of a 
recent publication identifying ATR inhibitors as active in Ewing sarcoma (Nieto-Soler et al., 
2016). Additionally, as previously reported, EWS/FLI was a biomarker of sensitivity to three 
different PARP inhibitors (Figure 3J) (Garnett et al., 2012).
THZ531 Is Synergistic with PARP Inhibitors in Ewing Sarcoma
While THZ1 was active in a mouse model of Ewing sarcoma, treatment with THZ1 as a 
single agent did not cure mice of disease, suggesting that combination therapy will be 
necessary to achieve full efficacy. Therefore, we sought to identify clinically tractable 
synergistic combinations with THZ1 in Ewing sarcoma models. Ovarian tumors with loss-
of-function mutations in CDK12 have reduced BRCA1 levels, deficient HR, and are highly 
sensitive to PARP inhibition (Joshi et al., 2014). Moreover, it was recently reported that pan-
CDK inhibition with dinaciclib can reverse PARP inhibitor resistance in BRCA-mutated 
triple negative breast cancer (Johnson et al., 2016). In Ewing sarcoma, studies have 
demonstrated that EWS/FLI physically interacts with PARP1, and induces PARP1 
expression (Brenner et al., 2012; Garnett et al., 2012; Stewart et al., 2014; Yang et al., 2013). 
These previous studies, in addition to our gene expression data identifying that THZ531 
preferentially downregulates HR repair genes in Ewing sarcoma, led us to hypothesize that 
THZ531 would synergize with PARP inhibitors. We used the Bliss independence and Loewe 
additivity models to assess synergy. The Bliss independence model computes a quantitative 
measure, excess over Bliss (eob), the difference between the observed combined effect and 
the expected combined effect of the two drugs (Bliss, 1956; Greco et al., 1995), while the 
Chou-Talalay Combination Index (CI) for the Loewe additivity model is a dose-effect 
approach that estimates the effect of combining two drugs based on the dose of each 
individual drug that produces the same quantitative effect (Chou, 2006; Chou and Talalay, 
1984). We observed strong synergy between THZ531 and olaparib in several Ewing sarcoma 
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cell lines using both models across a wide range of concentrations (Figure 4A, B). 
Moreover, we observed that THZ531 strongly synergizes with cisplatin, mitomycin C, the 
ATR inhibitor VE821, and the ATM inhibitor KU5593, in Ewing sarcoma cells (Figure 
S4A–D). Importantly, THZ531 does not synergize with vincristine, a microtubule inhibitor 
not classified as a DNA damaging agent (Figure S4E). This data provides further support 
that THZ531 mechanistically works through inhibiting DNA damage repair. Taken together, 
these findings suggest that Ewing sarcoma is a disease marked by DNA damage repair 
deficiency rendering tumor cells highly sensitive to these combination strategies.
To confirm the on-target activity of THZ531 in this combination effect, we knocked down 
CDK12 and CDK13, treated these cells with olaparib, and assayed for cell viability. We 
found that genetic suppression of CDK12, but not CDK13, sensitizes cells to olaparib 
(Figure 4C). This data supports that inhibition of CDK12 is responsible for the defects in 
DNA damage repair induced by THZ531. Furthermore, we demonstrated that suppression of 
EWS/FLI using two different hairpins renders cells more resistant to olaparib (Figure 4D), 
and when EWS/FLI is suppressed, synergy between THZ531 and olaparib is abrogated, 
consistent with the notion that EWS/FLI imparts vulnerability to defects in DNA repair 
(Figure 4E).
To further investigate the effects of these compounds on DNA damage and repair, we 
performed immunofluorescent analysis of γH2AX, an early sensor of DNA double strand 
breaks. THZ531 and olaparib alone induced γH2AX foci staining in Ewing sarcoma cells 
(Figure 5A, B), and the combination synergistically induced γH2AX foci formation, 
suggesting that this combination impairs the ability of Ewing sarcoma cells to repair DNA 
damage. To evaluate the effects on HR repair, we assayed RAD51 foci staining, a key 
regulator of HR-mediated repair. We observed a striking increase in RAD51 foci staining in 
Ewing sarcoma cells treated with olaparib (Figure 5C, D). Interestingly, THZ531 prevented 
the induction of RAD51 foci formation in olaparib-treated Ewing sarcoma cells, suggesting 
that THZ531 is impairing HR and the ability of RAD51 to be recruited to sites of DNA 
damage. We found that both THZ531 treatment and knockout of CDK12 led to a decrease in 
total RAD51 protein levels (Figure 5E, F). Furthermore, we observed a decrease in cell 
viability when RAD51 was knocked out by CRISPR-Cas9 (Figure 5G, H).
The Combination of CDK7/12/13 and PARP Inhibitors Is Highly Active in Ewing Sarcoma
We next assayed the in vivo efficacy of combining a CDK12 inhibitor and olaparib in a 
mouse model of Ewing sarcoma. Because THZ531 is not optimized for in vivo studies, we 
used the parental compound, THZ1. We first confirmed synergy between the parental 
molecule and olaparib in vitro (Figure S5A). We then established an A673 xenograft mouse 
model of Ewing sarcoma and performed a 4-arm study with twice-daily (BID) treatment of 
vehicle, 10 mg/kg THZ1, 50 mg/kg olaparib, and the combination of olaparib+THZ1 
delivered for 40 days. Olaparib and THZ1 as single agents each significantly decreased 
tumor growth rate and extended the survival of the mice (median survival = 18 days vehicle, 
32 days THZ1 and 28 days in the olaparib groups) (Figure 6A, B). A striking decreased 
tumor growth rate was observed when both drugs were used in combination (Figure 6A), 
and the combination treatment significantly extended survival compared to the vehicle 
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control or either single agent (Figure 6B). Seventy percent of mice in the combination arm 
were still alive by day 40 when treatment was ended (Figure 6B). Mice were followed out to 
day 150 without further treatment. At day 60, 40% (4 out of 10) of the mice in the 
combination group were still alive, whereas all of the mice in the vehicle and single agent 
arms had been sacrificed. Furthermore 20% of tumors in the combination arm had regressed 
to where they were no longer palpable (Figure 6B). In order to test the generalizability of 
this treatment strategy in Ewing sarcoma, we performed combination in vivo studies in a 
second xenograft mouse model using TC71 cells as well as a patient-derived xenograft 
(PDX) mouse model of this disease. In the TC71 xenograft study, both THZ1 and olaparib 
significantly reduced the tumor growth rate and extended survival as single agents (Figure 
6C, D), and the combination of THZ1 and olaparib significantly reduced tumor growth rate 
compared to either agent used alone (Figure 6C). The median survival of mice in the vehicle 
treated group was 30.5 days, compared to 42 days in the olaparib group, 38.5 days in the 
THZ1 group and 66.5 days in the combination group (Figure 6D). Furthermore, we 
established a PDX mouse model of Ewing sarcoma with a type I EWS/FLI fusion from a 
tumor resected from the fibula of a 12 year old patient at diagnosis (HSJD-ES-002). In this 
model, THZ1 as a single agent did not significantly reduce the tumor progression (Figure 
6E) but did significantly increase overall survival (Figure 6F). Importantly, the combination 
of THZ1 and olaparib strikingly reduced tumor progression and increased survival in this 
PDX (Figure 6E, F): vehicle, 23 days; olaparib, 42 days; THZ1, 44 days; and combination, 
56 days. Taken together, this drug combination resulted in a more profound and durable 
response than treatment with either drug alone.
Complete blood counts of all mice treated with THZ1 and olaparib and the combination of 
these two drugs in the TC71 xenograft mouse model of Ewing sarcoma were performed 
(Figure 6G). Importantly, we did not observe any hematopoietic toxicities after up to 40 days 
of treatment. Significant weight loss was also not observed in any of the three mouse models 
tested over long-term treatment (Figure S5B–D).
DISCUSSION
Pediatric, and even a subset of adult, cancers possess remarkably quiet genomes that are 
defined by sentinel genetic lesions (Lawrence et al., 2013). In principle, targeting these key 
lesions should make for a propitious therapeutic strategy; however, because most of the 
driver events involve transcription factors or loss of tumor suppressors, only a minority have 
been successfully pharmacologically addressed. For example, chromosomal translocations 
that result in EWS/ETS rearrangements characterizing Ewing sarcoma tumors have yet to be 
successfully targeted. EWS/FLI is a master transcription factor which activates an oncogenic 
transcriptional program. Unfortunately, targeting this transcription factor fusion protein has 
been a drug discovery challenge. Here, we demonstrate that synthetic lethal dependencies 
can be identified in the context of sentinel genetic lesions using chemical genomics. We 
determined that EWS/FLI incurs a synthetic lethal relationship with molecules that are 
involved in DNA damage/repair. Such a strategy could be applied broadly to other cancers 
with exceptionally simple genomic landscapes.
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DNA damaging agents, such as doxorubicin and etoposide, form the backbone of Ewing 
sarcoma therapy. Moreover, Ewing sarcoma is highly radiation responsive, suggesting that 
Ewing sarcoma is particularly sensitive to DNA damage. Intriguingly, three independent 
studies reported that Ewing sarcoma is sensitive to PARP inhibitors (Brenner et al., 2012; 
Garnett et al., 2012; Stewart et al., 2014; Yang et al., 2013). In one study, PARP1 was found 
to physically interact with EWS/FLI and act as a transcriptional co-regulator of the 
oncogenic transcription factor fusion protein (Brenner et al., 2012). Furthermore, EWS/FLI 
was found to induce PARP1 expression in a positive feed forward loop (Brenner et al., 
2012). In a second study, a chemical genomics screen across 639 cancer cell lines was 
conducted to identify new genotype:chemosensitivity relationships in cancer (Garnett et al., 
2012; Yang et al., 2013). The connection between EWS/ETS rearranged Ewing sarcoma and 
response to PARP inhibitors was highlighted. Suppressing EWS/FLI in Ewing sarcoma cells 
was reported to render resistance to PARP inhibition, a finding which we recapitulate in the 
current study (Garnett et al., 2012). In our own study of the exquisite sensitivity to the 
CDK7/12/13 inhibitor THZ1, we found that CDK12 was an essential target for their 
selective sensitivity, and mechanistically, suppression of RAD51 expression impaired the 
growth of EWS/FLI-expressing Ewing sarcoma cells. Our data are consistent with prior 
studies demonstrating that CDK12 regulates the expression of DNA damage repair genes, 
most notably, BRCA1, ATR, FANCl and FANCD2 (Blazek et al., 2011). Furthermore, 
CDK12 was shown to bind to these HR-related genes and was necessary for the 
phosphorylation of the CTD of RNA Pol II at Ser2 at these genes (Ekumi et al., 2015).
While additional studies will be necessary to dissect the precise mechanisms by which 
EWS/FLI sensitizes Ewing sarcoma cells to compounds that induce DNA damage and/or 
prevent its repair, the results of these studies are readily translatable. Clinical trials testing 
PARP inhibitors in patients with BRCA-deficient tumors have demonstrated anti-tumor 
efficacy and provide an example of successfully exploiting synthetic lethal relationships for 
therapeutic benefit (Kaelin, 2005; Sonnenblick et al., 2015). The promising activity of PARP 
inhibitors in trials for HR deficient tumors, and the convergence of multiple groups 
demonstrating PARP inhibitor activity in Ewing sarcoma, prompted much interest in their 
clinical testing in this disease, one for which there are no approved targeted therapeutics and 
for which cure rates remain quite poor for patients with metastatic or relapsed disease. 
Despite promising preclinical data demonstrating sensitivity of Ewing sarcoma cells to 
PARP inhibitors (Norris et al., 2014; Vormoor and Curtin, 2014), a Phase II clinical trial 
testing olaparib in patients with relapsed/refractory Ewing sarcoma failed to demonstrate 
anti-tumor efficacy (Choy et al., 2014). These disappointing results highlighted the need to 
identify agents to use in combination with PARP inhibitors to improve their efficacy.
In the current study, we hypothesized that a CDK12 inhibitor would synergize with a PARP 
inhibitor because CDK12 loss-of-function mutations in ovarian cancer have rendered 
sensitivity to PARP inhibitors (Bajrami et al., 2014; Joshi et al., 2014). Indeed, THZ531/
THZ1 and olaparib were highly synergistic in vitro, and THZ1 and olaparib were highly 
active in combination in vivo with a subset of the mice remarkably “cured” of disease 
without bone marrow toxicity. It is important to note that some of the anti-proliferative 
effects of THZ1 in vivo may not be due solely to CDK12 inhibition, as the molecule also 
targets CDK7 and CDK13, and the optimization of CDK12 selective inhibitors for in vivo 
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studies is still needed. However, the strong synergy observed between THZ1 and olaparib is 
likely mediated by THZ1’s inhibitory effects on CDK12, which our data suggests impairs 
HR repair. With this class of compounds in early phase clinical trials, this study has 
translational potential for patients with Ewing sarcoma and provides the preclinical 
validation for second-generation clinical trials. Moreover, this combination is predicted to be 
broadly applicable for cancers with BRCA1/2 mutations, which are highly sensitive to PARP 
inhibitors.
Contact for Reagent and Resource Sharing
Requests for resources and reagents should be directed to and will be fulfilled by the Lead 
Contact, Kimberly Stegmaier (kimberly_stegmaier@dfci.harvard.edu)
Experimental Model and Subject Details
Cell Lines
A673 cells (female) were cultured in DMEM + 10% FBS + 1mM sodium pyruvate + 1% 
PSQ. TC32 (female), TC71 (male) and SJSA1 (male) cells were cultured in RPMI + 10% 
FBS +1% PSQ. EW8 (male), U2OS (female), and SKNMC (female) cells were cultured in 
DMEM + 10% FBS + 1% PSQ. EWS502 cells (female) were cultured in DMEM + 15% 
FBS + 1% PSQ. RDES (male), EWS834 (female), and SKNEP1 (female) cells were 
cultured in DMEM + 20% FBS + 1% PSQ. SKES1 (male) cells were cultured in McCoys5a 
+ 15% FBS + 1% PSQ. Whole exome sequencing, RNA sequencing and STR genotyping of 
all Ewing sarcoma cell lines used in these studies were previously performed to validate cell 
line identity (Crompton et al., 2014).
In Vivo Tumor Models
A PDX mouse model of Ewing sarcoma with a type I EWS/FLI fusion was established from 
a tumor resected from the fibula of a 12 year old patient at diagnosis (HSJD-ES-002). HSJD-
ES-002 was established in athymic nude mice (Harlan, Barcelona, Spain) as previously 
described (Monterrubio et al., 2015; Ordonez et al., 2015). Informed consent for the use of 
clinical data and biological material was obtained from the patient and all studies were 
approved by the ethics review committee at the Sant Joan de Déu Hospital in Esplugues de 
Llobregat. All dosing studies were performed at the Dana-Farber Cancer Institute, and all 
animal protocols were approved by the Dana-Farber Cancer Institute Animal Care and Use 
Committee. Nude mice were maintained according to institutional guidelines.
Single agent THZ1 study—Three million TC32 Ewing sarcoma cells were implanted 
subcutaneously into the right flank of 7–8 week old female nude mice. Following 
engraftment, mice with palpable tumors were divided into two groups and treated with 10 
mg/kg THZ1 or vehicle control administered IP BID. Tumors were measured twice per 
week and mice were followed for survival. Statistical significance was determined by Log-
rank test for survival curves.
THZ1 and olaparib combination study—Three million A673 or TC71 cells were 
subcutaneously implanted into the right flanks of 7–8 week old nude female mice. For PDX 
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studies, 1 mm3 viably frozen tumor chunks were dipped in matrigel and implanted into the 
right flanks via minor surgery. When tumors measured 100–150 mm3, mice were divided 
into four groups: vehicle control, THZ1, olaparib, and THZ1 and olaparib in combination. 
THZ1 was administered IP BID at 10 mg/kg, and olaparib was administered PO BID at 50 
mg/kg. Tumors were measured twice per week and mice were followed for survival. 
Statistical significance was determined by log-rank test for survival curves.
Method Details
Western Blotting
Cells were lysed in Cell Signaling Lysis Buffer (Cell Signaling Technology) supplemented 
with Complete, EDTA free Protease Inhibitor Cocktail (Roche Diagnostics) and PhosSTOP 
Phosphatase Inhibitor (Roche Diagnostics). Protein concentrations were determined by the 
Bradford protein assay. Protein samples were separated by SDS-PAGE and transferred to 
PVDF membranes. Membranes were incubated with primary antibodies directed against 
CDK7 (Cell Signaling Technology Cat. No. 2090S), CDK12 (Cell Signaling Technology 
Cat. No. 11973), CDK13 (Bethyl Cat. No. A301-458A), Cyclin K (Abcam ab130475), p-
Ser2-RNA-Pol II (Bethyl Cat. No. A300654A), p-Ser5-RNA-Pol II (Bethyl Cat. No. 
A300-655A), p-Ser7-RNA-Pol II (Millipore Cat. No. 04-1570), total RNA-Pol II (Santa 
Cruz Cat. No. sc-17798), PARP (Cell Signaling Technology Cat. No. 9542), RAD51 (Cell 
Signaling Technology Cat. No. 8875), FLI1 (Santa Cruz Biotechnology Cat. No. sc-356), 
Vinculin (Abcam Cat. No. ab18058), GAPDH (Santa Cruz Biotechnology Cat. No. 
sc-137179), and β-Actin (Cell Signaling Technology Cat. No. cs3700). Horseradish 
peroxidase (HRP) conjugated secondary antibodies were used. Blots were visualized by 
enhanced chemi-luminescence (ThermoFisher Scientific).
Quantitative PCR
RNA was extracted from cells with the RNeasy Kit and on-column DNA digestion (Qiagen). 
cDNA was prepared using M-MLV Reverse Transcriptase (ThermoFisher Scientific). 
Taqman probes for RPL13A (Hs01926559_g1), BRCA1 (Hs01556193_m1), RAD51 
(Hs00427442_m1), FANCF (Hs00256030_s1), and XRCC2 (Hs03044154_m1) were 
obtained from Life Technologies. Data were collected in technical and biological triplicate 
and analyzed using the ΔΔCT method.
Compounds
THZ1, THZ1R, THZ531, and THZ531R were synthesized by the Gray Laboratory (Dana-
Farber Cancer Institute). Olaparib was obtained from Selleck Chemicals (Cat. No. S1060) 
for in vitro studies, and ApexBio (Cat. No. A4154) for in vivo studies. For the in vivo 
studies, THZ1 was solubilized in 10% DMSO, 90% D5W, and olaparib was solubilized in 
10% DMSO, 90% HPBCD.
THZ1-biotin immunoprecipitation
Cell were treated with THZ1 or THZ531 for 6 hr and lysed with 50 mM Hepes pH 7.4, 150 
mM NaCl, 1% NP40, 5 mM EDTA, and protease and phosphatase inhibitors. Samples were 
incubated with 1 µM THZ1-biotin or DMSO overnight at 4°C. Streptavidin beads were 
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added to each sample and incubated for 2 hr at 4°C. Samples were washed in lysis buffer 
and SDS loading dye was added to each sample and boiled at 95°C before loading onto 
western blot gels.
Genome-scale CRISPR-Cas9 Screening
The genome-scale CRISPR-Cas9 screen was conducted using the Broad Institute’s Avana 
library and analyzed using the CERES algorithm as previously described (Meyers at al., 
2017). The data used for the analysis of CDK7, CDK12, and CDK13 included the gene 
effects as predicted by the CERES algorithm.
RNA Extractions and Synthetic RNA Spike-in
RNA was extracted from equal numbers of Ewing sarcoma cells using the RNeasy kit 
(Qiagen) according to the manufacturer’s instructions. A fixed amount of External RNA 
Controls Consortium (ERCC) RNA Spike-In Mix (Ambion, 4456739) was added to the total 
RNA (Loven et al., 2012).
Gene Expression Profiling
Gene expression profiling was performed with spiked-in RNA samples using Human 
PrimeView arrays (Affymetrix) as previously described (Kwiatkowski et al., 2014). For gene 
expression studies, the CEL data files were subjected to the quality control tests based on 
distance between arrays, array intensity distribution and variance mean dependence, which 
are implemented in the ArrayQuality R package available at Bioconductor v 3.2 
(www.bioconductor.org). All CEL files passed the test. CEL files were processed as 
previously described (Kwiatkowski et al., 2014). Briefly, the raw expression values for each 
probe were summarized using Mas5, and Mas5-normalized probe set values were 
normalized across samples using Loess normalization with ERCC probes as the reference 
subset. The probe with the highest average signal was taken for each RefSeq transcript. 
Replicates were averaged for each transcript. All probe sets with an average log2 expression 
below 4 were considered under-expressed and they were designated as “filtered”. Out of the 
49,293 probe sets on the Affymetrix PrimeView Human Gene Expression Array, 44,125 
probe sets remained after filtering. The data from the 44,125 probe sets was further 
collapsed to 11,963 non-redundant genes with distinct GRCh37/hg19 HUGO symbols, by 
assigning to each gene the probe set with the maximum average expression intensity. These 
genes were considered expressed for Figure 3A and F. For each cell line, significant hits 
were selected based on the cutoffs: 1 for absolute fold change, 0.05 for permutation p value, 
and 0.05 for False Discovery Rate. Transcript fold-changes were performed by log2-
transforming the transcript values in both samples plus one pseudo-count and subtracting the 
log2-transformed values. In Figure 3F, the top 30% of transcripts ranked by DMSO signal 
were taken.
Gene Set Enrichment Analysis
The Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 and the 
GSEA v2.1.0 software were used to identify functional associations of the molecular 
phenotypes induced by THZ531 at 100 nM vs. vehicle and by THZ531 at 500 nM vs. 
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vehicle. Gene sets with less than 15 genes or more than 500 genes were excluded from the 
analysis. Gene sets with an FDR ≤ 0.25 and a nominal p value ≤ 0.05 were considered 
significant hits. The enrichment results for THZ531 at 100 nM vs. vehicle and for THZ531 
at 500 nM vs. vehicle were visualized on GSEA plots and heatmaps for selected gene 
signatures. The molecular gene set signatures of THZ531 100 nM and THZ531 500 nM vs. 
vehicle were visualized as dots in the volcano plots of normalized enrichment scores (NES) 
vs. −log10(p value) scores.
Comparative Marker Analysis
The Comparative Marker Selection module from GenePattern v3.9.6 was employed to 
identify individual genes that were differentially expressed between treated and vehicle 
conditions. The analysis was performed on the log2 normalized expression data by applying 
a 2-sided signal-to-noise ratio (SNR) test followed by 1000 permutations of phenotype 
labels. The settings for the SNR parameters were log-transformed-data: yes, complete:no, 
balanced:no, smooth p values: yes. Gene signatures (down and up) for 100 nM THZ531 vs. 
vehicle and 500 nM THZ531 vs. vehicle were defined separately for each of the A673 and 
TC32 cell lines based on the cut-offs SNR permutation p value ≤ 0.05, Benjamini-Hochberg 
false discovery rate (FDR) ≤ 0.05, and absolute fold change [FC] ≥ 2. A core molecular 
signature for the differential expression of A673 and TC32 cell lines was defined by 
overlapping the lists of genes which are significantly differentially expressed (down and up, 
respectively) in either cell line. The significance of the overlap of the lists of genes 
differentially expressed in A763 vs. TC32 cell lines was estimated based on the two-tailed 
Fisher test. The correlation between the expression fold changes induced by THZ531 vs. 
vehicle in the A673 and TC32 cell lines was estimated by fitting a linear regression model. 
The differentially expressed genes induced by THZ531 in the A673 and TC32 cell lines 
were visualized as highlighted dots in scatter plots of log2 fold change of expression.
Super-Enhancer Analysis
The TC32 enhancer and FLI1 region/gene target data were created and published by the 
Stegmaier lab (Kennedy et al., 2015). The A673 enhancer and FLI1 region/gene target data 
were created and published by the Rivera lab (Riggi et al., 2014). Peaks were called using 
MACS 1.4.2 with corresponding input control and two parameter sets:-p 1e-9 --keep-dup=1 
and -p 1e-9 --keep-dup=all. The collapsed union of peaks was used as input for ROSE. 
ROSE was run with parameters -t 1000 -s 12500 and corresponding input control. ROSE-
defined enhancers were assigned to the single nearest expressed gene whose transcription 
start site was closest to the center of the enhancer. Expressed genes are defined as the top 2/3 
of RefSeq transcripts ranked by their promoter H3K27ac levels, where promoters are 
defined as 1kb regions centered on each transcription start site and H3K27ac level is 
calculated using bamToGFF (https://github.com/BradnerLab/pipeline) with parameters -e 
200 -m 1 -r -d.
Leading Edge Analysis The leading edge analysis implemented in the GSEA platform http://
software.broadinstitute.org/gsea/index.jsp was employed to analyze the collection of 
“leading edge” genes, (i.e., the genes which simultaneously (i) are in multiple significantly 
enriched DNA Damage and DNA Repair gene sets and (ii) are differentially expressed by 
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the THZ531 100 nM treatment vs. vehicle). The collection of 33 leading edge genes that 
belong to at least four DNA Damage and DNA Repair gene sets enriched in the THZ531 vs. 
vehicle signature was visualized.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde for 10 minutes at RT, permeabilized with ice 
cold methanol for 5 minutes at −20°C, and blocked in 3% BSA in PBS for 30 minutes at RT. 
Cells were then incubated in primary antibodies against RAD51 (Abcam, clone 14B4), or 
γH2AX (S139, Millipore, clone JBW301). Alexa-Fluor conjugated secondary antibodies 
were used (Life Technologies). Cell nuclei were stained using DAPI reagent (Cell Signaling 
Technology Cat. No. 8961). One hundred cells per sample were counted. A cell was counted 
as γH2AX or RAD51 positive only if >10 foci per nucleus were identified.
Colony Formation Assays
A base layer of 1:9 6% agar in media was poured into 24 well plates. Cells were plated in a 
0.3% agar/media solution on top of the base layer at a concentration of 15,000 cells/well. 
Cells were fed with growth media on the first and sixth day after plating, stained with MTT, 
and imaged once colonies were visible. Colonies were counted using Image Quant (GE 
Healthcare).
Annexin V/PI Staining
Apoptosis was measured using the Annexin V: FITC Apoptosis Detection Kit per the 
manufacturer’s protocol (BD Pharmingen, San Jose, CA, USA).
shRNA and CRISPR Studies
Lentivirus was generated by transfecting 293T cells with the appropriate lentiCRISPRv2 
sgRNA vector or the appropriate pLKO shRNA vector, and the packaging plasmids 
pCMV8.9 and pCMV-VSVG, using Fugene 6 per the manufacturer’s instructions 
(Promega). Forty-eight hrs after transfection, media containing virus was filtered through a 
0.45 µM filter. Ewing sarcoma cell lines were transduced in 10 cm plates with 3 ml virus, 3 
ml of growth media and 8 µg/ml polybrene (Sigma-Aldrich). Forty-eight hrs post-infection, 
cells were selected in puromycin–containing media. Five days post-selection (CRISPR 
studies) or three days post-selection (shRNA studies), cells were harvested for protein, 
colony formation and viability assays. CRISPR guide sequences were designed using the 
Broad Institute’s sgRNA designer tool (http://www.broadinstitute.org/rnai/public/analysis-
tools/sgrna-design-v1).
EWS/FLI knockdown was achieved using a TRIPZ inducible lentiviral vector system. Cells 
with either an shRNA against EWS/FLI or non-targeting control were treated with 
doxycycline every 48 hr for seven days. EWS/FLI knockdown was confirmed by western 
blotting. See Supplemental Table S6 for a list of all shRNA and sgRNA sequences and 
vector information.
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Cell Viability and Synergy Studies
Cells were seeded onto 384-well tissue culture treated plates at a density of 25,000 cells/ml. 
After treatment with a compound or a combination of compounds, cells were analyzed for 
cell viability on days zero, three, five, and seven, using the Cell-TiterGlo luminescent assay 
(Promega) per the manufacturer’s instructions. Luminescence was read on a Fluostar Omega 
Reader (BMG Labtech).
Chou-Talalay Combination Index for Loewe Additivity
Loewe additivity is a dose-effect model which states that additivity occurs in a two-drug 
combination if the sum of the ratios of the dose vs. the median-effect for each individual 
drug is 1. In this model, combination index (CI) scores estimate the interaction between the 
two drugs. If CI < 1, the drugs have a synergistic effect and if CI > 1, the drugs have an 
antagonistic effect. CI = 1 means the drugs have additive effect. Chou and Talalay (Chou and 
Talalay, 1984) showed that Loewe equations are valid for enzyme inhibitors with similar 
mechanisms of action -- either competitive or non-competitive toward the substrate. The 
combination index (CI) coefficients were computed based on the Chou-Talalay Median 
Effect model as implemented in CalcuSyn v2.11 (http://www.biosoft.com/w/calcusyn.htm). 
The degree of interaction between drugs was estimated according to the classification 
presented by Chou-Talalay (Chou and Talalay, 1984). The CI scores were computed for the 
range of concentrations of drug combinations where the effect of an individual drug was less 
than a fractional inhibition of 0.9. If the fractional inhibition score in paired combination 
with DMSO and with the other drug is > 0.9, this dose was eliminated from the analysis 
since the additional effect of the second drug could not be reliably calculated.
The Bliss Independence Method
Bliss independence (Bliss, 1956) is an effect-based strategy that compares the effect 
resulting from the combination of two drugs directly to the effects of its individual 
components.
The model predicts that if the individual drugs have the inhibitory effects f1 and f2 then the 
expected combined effect of the two drugs is:
The difference between the observed combined effect f12 and the expected combined effect 
of the two drugs is called the Excess over Bliss (eob): eob = f12 − E(f12)
Positive eob values are indicative of a synergistic interaction, whereas negative eob values 
are indicative of antagonistic behavior. Null eob values indicate no drug interaction.
Quantification and Statistical Analyses
GSEA v2.1.0, GraphPad PRISM 7, R 3.2.3 and Python 2.7.2 software packages were used to 
perform the statistical analyses. Statistical tests used are specified in the Figure legends. 
Errors bars represent standard deviation, unless otherwise stated. The threshold for statistical 
significance is P < 0.05, unless otherwise specified.
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Data and Software Availability
Gene expression data have been deposited to GEO (accession no: GSE82270).
It can be accessed at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE82270
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SIGNIFICANCE
Here we report that Ewing sarcoma is a disease with exquisite sensitivity to the covalent 
small molecule CDK7/12/13 inhibitors, THZ1 and THZ531. These compounds act, in 
part, through inhibition of CDK12 and the subsequent suppression of genes involved in 
DNA damage repair. The preferential sensitivity of Ewing sarcoma cells to THZ1/
THZ531 is imparted by the tumor-specific expression of the fusion oncoprotein EWS/
FLI. The combination of these molecules with PARP inhibitors showed prominent 
synergy in multiple models of Ewing sarcoma without apparent toxicity. With this class 
of compounds moving toward the clinic, this study has promising translational potential 
for patients with Ewing sarcoma and important translational relevance to other tumors 
that are sensitive to PARP inhibitors.
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HIGHLIGHTS
1. Ewing sarcoma cells are highly sensitive to CDK7/12/13 inhibitors.
2. Tumor-specific EWS/FLI expression is synthetic lethal with suppression of 
CDK12.
3. CDK12/13 inhibitors impair DNA damage repair in fusion-positive Ewing 
sarcoma.
4. CDK12/13 and PARP inhibitors are highly synergistic in Ewing sarcoma.
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Figure 1. Extensive profiling of THZ1 highlights exceptional sensitivity of Ewing sarcoma cells
A. A diverse panel of 1,081 cancer cell lines was treated with DMSO or 9.76 nM THZ1 for 
72 hr and assayed for cell viability. Shown are the mean relative viabilities +/− SEM for 
each tumor type with at least eight cell lines screened. Ewing sarcoma cell lines are in red. 
B. Western blot demonstrating the effects of THZ1 on p-RNA Pol II in Ewing sarcoma cell 
lines at 6 hr. β-Actin, loading control. C. Concentration-dependent effects of THZ1 on the 
percentage of Annexin V+ cells measured by flow cytometry at 24 hr. Data are presented as 
mean values ± SD of triplicate points (t-test). D. Western blot demonstrating the effects of 
THZ1 on PARP cleavage at 24 hr. GAPDH, loading control. E. Colony formation in soft 
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agar of Ewing sarcoma cell lines treated with THZ1 for 14 days. The experiment was 
conducted in biological triplicate. Data shown is a representative experiment of mean values 
± SD of technical duplicates (t-test). F. Tumor volume measurements of TC32 Ewing 
sarcoma xenografts treated with 10 mg/kg THZ1 IP or vehicle control (10% DMSO in 
D5W) IP BID. Data are plotted out to day 32 when >50% of mice in the vehicle group were 
still alive and presented as mean values ± SD (n=8 per arm) (t-test). G. Kaplan Meier 
survival curves for the experiment described in F. Treatment was stopped on day 42 (arrow) 
and mice were followed for survival (Log-rank Mantel Cox test). *p value <0.05, **p value 
<0.01, ***p value <0.001, ****p value <0.0001. See also Figure S1.
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Figure 2. The activity of THZ1 in Ewing sarcoma cell lines is attributed to CDK12 inhibition
A. Dose-response curves of Ewing sarcoma cell lines (black) and osteosarcoma cell lines 
(gray) treated with THZ1 (CDK7/12/13 inhibitor), THZ531 (CDK12/13 selective inhibitor), 
or THZ531R (derivative of THZ531 that lacks the covalent binding moiety) for 72 hr. Data 
are plotted as the percentage of luminescence relative to DMSO controls. The experiment 
was performed in biological triplicate. Results are presented as mean values of a 
representative experiment ± SD of 8 technical replicates. B–C. THZ1-biotin 
immunoprecipitation of samples treated with THZ1 or THZ531 and probed for Cyclin K 
(CycK) or Cyclin H (CycH) in A673 cells (B) and TC32 cells (C). The experiment was 
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performed in biological duplicate. D. Immunoblot of A673 cells infected with a luciferase 
shRNA control (shLuc) or shRNAs against Cyclin K (shCycK) and probed for Cyclin K 
expression five days post-infection. GAPDH, loading control. E. Relative viability of A673 
cells infected with shLuc or shCycK ten days post-infection. Data are plotted as the 
percentage of luminescence relative to shLuc control. The experiment was performed in 
biological triplicate. Results are presented as mean values of a representative experiment ± 
SD of 8 technical replicates. (Statistical significance is calculated for each individual hairpin 
compared to the control hairpin, t-test). F. Immunoblot of A673 cells infected with a 
luciferase shRNA control or shRNAs against CDK12 or CDK13 five days post-infection. 
GAPDH, loading control. G. Relative viability of cells infected with hairpins against 
luciferase, CDK12 or CDK13 ten days post-infection. Data are plotted as the percentage of 
luminescence relative to shLuc control. The experiment was performed in biological 
triplicate. Results are presented as mean values of a representative experiment ± SD of 8 
technical replicate. (Statistical significance is calculated for each individual hairpin 
compared to the control hairpin, t-test). H. Immunoblot of A673 cells infected with a non-
targeting control sgRNA (NT CTRL) or three different guide RNAs against CDK12 
(sgCDK12) seven days post-infection. GAPDH, loading control. I. Relative viability of cells 
infected with a NT CTRL sgRNA or sgRNAs targeting CDK12 fourteen days post-infection. 
Data are plotted as the percentage of luminescence relative to NT control. The experiment 
was performed in biological triplicate. Results are presented as mean values of a 
representative experiment ± SD of 8 technical replicates. (Statistical significance is 
calculated for each individual hairpin compared to the control hairpin, t-test). ****p value 
<0.0001. See also Figure S2 and Tables S1 and S2.
Iniguez et al. Page 26
Cancer Cell. Author manuscript; available in PMC 2019 February 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. THZ531 treatment globally downregulates mRNA levels with enrichment for 
suppression of DNA damage/repair-related genes
A. A673 and TC32 cells were treated with THZ531 for 6 hr in duplicate. Heatmaps display 
the log2 fold change (Log2FC) in gene expression for THZ531 vs. DMSO treatment. B. 
Log2FCs in gene expression in A673 cells (x-axis) or TC32 cells (y-axis) treated with 100 
nM THZ531 vs. DMSO (left) or 500 nM THZ531 vs. DMSO (right). Genes are represented 
as dots. Dots corresponding to genes significantly downregulated by THZ531 in both A673 
and TC32 lines are highlighted blue. Dots corresponding to genes significantly upregulated 
by THZ531 in both A673 and TC32 cells are highlighted red. The Log2FCs in gene 
expression in A673 cells vs. TC32 cells are positively correlated with 100 nM THZ531 (R2 
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= 0.67) and 500 nM THZ531 (R2= 0.72). C. Gene Ontology analysis of the top 5% of 
sensitive genes to 100 nM THZ531 treatment. D. Volcano plot depicting GSEA for 
enrichment from the MSigDB v5 collections, c2, and c5, as well as published EWS/FLI 
genes sets, in the genes significantly downregulated by 100 nM THZ531 in both A673 and 
TC32 cells. DNA damage response (DDR) gene sets are highlighted in red and EWS/FLI1 
gene sets are highlighted in black. Gene sets that fall above the red line are statistically 
significant. Positive normalized enrichment scores (NES) indicate upregulation of genes 
sets, whereas, negative NES indicate downregulation of gene sets. ns = not significant. E. 
Individual GSEA plots for enrichment of the indicated gene sets among THZ531 
downregulated genes. F. Graph showing the Log2FC in gene expression after 100 nM and 
500 nM THZ531 treatment with select DDR genes highlighted. G–H. Dose-response curves 
of A673 shCTRL and shEWS/FLI (G) and TC32 shCTRL and shEWS/FLI cells (H) 
generated with two distinct hairpins treated with THZ531 for 72 hr. Data are plotted as the 
percentage of luminescence relative to DMSO controls. Experiments were conducted in 
biological triplicate. Results are presented as mean values of a representative experiment ± 
SD of 8 technical replicates. Western blots demonstrating EWS/FLI knockdown are shown 
to the right of the dose response curves. I. Relative viability of A673 shCTRL and 
shEWS/FLI cells infected with hairpins against CDK12 seven days post-infection. Data are 
plotted as the percentage of luminescence relative to shCTRL cells. The experiment was 
conducted in biological triplicate. Results are presented as mean values of a representative 
experiment ± SD of 8 technical replicates. (Statistical significance is calculated for the 
viability effect of each CDK12 hairpin in the context of shEWS/FLI compared to shCTRL, 
****p value <0.0001, t-test). J. EWS/FLI biomarker data from the Genomics of Drug 
Sensitivity in Cancer (http://cancerrxgene.org, release 21-41-36, June 2 2017). Enrichment 
of drugs targeting DDR Pathways among drugs in which EWS/FLI is a biomarker of 
sensitivity was calculated by Two-tailed Fisher exact test: Odds Ratios = 3.81, p value = 
0.0078. Significant hits cut-offs: IC50 Effect < −0.5, p value < 0.001. PARP inhibitors are 
shown as red triangles, additional DNA damage and repair drugs as red circles, and other 
chemical hits as black circles. Olaparib was screened at 5 and 10 nM. See also Figures S3 
and Tables S3–S5.
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Figure 4. THZ531 synergy with olaparib is EWS/FLI dependent
A. Excess over Bliss synergy plots for serial dilutions of THZ531 in combination with 
olaparib in A673, TC71 and EW8 cells. Excess over Bliss scores > 0 indicate drug synergy, 
whereas negative scores indicate antagonism. B. Chou-Talalay normalized isobolograms of 
data presented in (A). Plots depict combination index scores over a range of concentrations 
of THZ531 and olaparib. The coordinates of the CI scores are d1/Dx1 and d2/Dx2 where Dx1 
is the concentration of drug 1 (THZ531) that alone produces the fractional inhibition effect 
x, and Dx2 is the concentration of drug 2 (olaparib) that alone produces the fractional 
inhibition effect x. CI < 1 = synergism, CI > 1 = antagonism. The red line displayed is the 
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line of additivity. C. Dose-response curves of A673 cells infected with hairpins against 
luciferase, CDK12, or CDK13, and treated with olaparib for five days. Data are plotted as 
the percentage of luminescence relative to shLuc control. The experiment was conducted in 
biological duplicate. Results are presented as mean values of a representative experiment ± 
SD of 8 technical replicates. D. Dose-response curves of A673 shCTRL and shEWS/FLI 
cells treated with olaparib for five days. Data are plotted as the percentage of luminescence 
relative to DMSO controls. The experiment was conducted in biological triplicate. Results 
are presented as mean values of a representative experiment ± SD of 8 technical replicates. 
E. THZ531 and olaparib excess over Bliss synergy plots in A673 shCTRL and shEWS/FLI 
cells. The experiment was conducted in biological triplicate. See also Figure S4.
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Figure 5. THZ531 and olaparib synergistically induce DNA damage in Ewing sarcoma cells
A–D. γH2AX foci staining (A) and quantification (B), and Rad51 foci staining (C) and 
quantification (D) in A673 cells treated with olaparib (2 µM) or THZ531 (25 nM) alone and 
in combination for 72 hr. Nuclei are stained with DAPI. Scale bars represent 5 µM. One 
hundred cells per sample were counted and results are presented as mean values ± SD (t-
test). A cell was counted as positive if >10 foci per nucleus were identified. E. Immunoblot 
of A673 cell lysates treated with DMSO or THZ531 and probed for RAD51 expression. 
Vinculin, loading control. F. Immunoblot of A673 cells infected with a NT CTRL or guide 
RNAs targeting CDK12 and probed for CDK12 and RAD51. Vinculin, loading control. 
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Densitometric quantification is shown below the blots for CDK12 and RAD51. Values are 
normalized to the vinculin expression for each condition and then to the expression in the 
NT CTRL. G. Immunoblot of A673 cells infected with a NT CTRL or guide RNAs targeting 
RAD51 seven days post-infection. Vinculin, loading control. H. Viability of cells infected 
with sgRNAs against RAD51 14 days post-infection. Data are plotted as the percentage of 
luminescence relative to NT CTRL. The experiment was conducted in biological triplicate. 
Results are presented as mean values of a representative experiment ± SD of 8 technical 
replicates (t-test). **p value <0.01, ***p value <0.001, ****p value <0.0001.
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Figure 6. THZ1 and olaparib are strongly synergistic in several mouse models of Ewing sarcoma
A. Tumor volume measurements of an A673 xenograft mouse model treated with vehicle, 10 
mg/kg THZ1 IP BID, 50 mg/kg olaparib PO BID, or the combination of olaparib+THZ1. 
Treatment was stopped on day 40. Data for a given time point were plotted if >50% of mice 
in the group were alive. Data are plotted as mean values ± SD (n=10 per arm). B. Kaplan 
Meier survival curves for the experiment described in (A). Arrow indicates treatment end 
date. C. Tumor volume measurements of a TC71 xenograft mouse model treated with 
vehicle, 10 mg/kg THZ1 IP BID, 50 mg/kg olaparib PO BID, or the combination of olaparib
+THZ1. Treatment was stopped on day 40. Data for a given time point were plotted if >50% 
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of mice in the group were alive. Data are plotted as mean values ± SD (n=10 per arm). D. 
Kaplan Meier survival curves for the experiment described in (C). Arrow indicates treatment 
end date. E. Tumor volume measurements of a PDX mouse model of Ewing sarcoma treated 
with vehicle, 10 mg/kg THZ1 IP BID, 50 mg/kg olaparib PO BID, or the combination of 
olaparib+THZ1. Treatment was stopped on day 28. Data for a given time point were plotted 
if >50% of mice in the group were alive. Data are plotted as mean values ± SD (n=8 per 
arm). F. Kaplan Meier survival curves for the experiment described in (E). Arrow indicates 
treatment end date. (ns = not significant, *p value <0.05, **p value <0.01, ***p value 
<0.001. ****p value <0.0001. 2 way ANOVA with Tukey post hoc test was performed for 
tumor volume graphs and Log-rank Mantel Cox test was performed for survival curves. G. 
Complete blood count analysis of TC71 xenografted mice treated as in (C) at time of 
sacrifice. Mice were sacrificed when tumors reached 2 cm in length, and in some cases, mice 
were off treatment at time of sacrifice. Two mice that were never on treatment were included 
as additional controls. The gray areas mark the normal range for each blood cell count and 
are measured in thousands per cubic milliliter (K/µL) of blood. WBC = white blood cells, 
NE = neutrophils, MO = monocytes, LY = lymphocytes, Hb = hemoglobin, PLT = platelets. 
Data are presented as mean values with whiskers representing min and max values and the 
outer edges of the boxes representing the 25th percentile (lower quartile) and 75th percentile 
(upper quartile). ns = not significant, *p value <0.05, **p value <0.01, ***p value <0.001, 
****p value <0.0001. See also Figures S5.
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